BioMarin

YTD

ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,221

Employees3,221

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,221

Employees3,221

BMRN Key Statistics

Market cap

11.75B

Market cap11.75B

Price-Earnings ratio

33.56

Price-Earnings ratio33.56

Dividend yield

—

Dividend yield—

Average volume

2.57M

Average volume2.57M

High today

$61.52

High today$61.52

Low today

$59.16

Low today$59.16

Open price

$60.18

Open price$60.18

Volume

2.59M

Volume2.59M

52 Week high

$73.51

52 Week high$73.51

52 Week low

$50.76

52 Week low$50.76

Stock Snapshot

With a market cap of 11.75B, BioMarin(BMRN) trades at $61.12. The stock has a price-to-earnings ratio of 33.56.

On 2026-03-06, BioMarin(BMRN) stock moved within a range of $59.16 to $61.52. With shares now at $61.12, the stock is trading +3.3% above its intraday low and -0.7% below the session's peak.

Trading volume for BioMarin(BMRN) stock has reached 2.59M, versus its average volume of 2.57M.

Over the past 52 weeks, BioMarin(BMRN) stock has traded between a high of $73.51 and a low of $50.76.

BMRN News

TipRanks 3d

BioMarin price target raised to $105 from $80 at Barclays

Barclays raised the firm’s price target on BioMarin (BMRN) to $105 from $80 and keeps an Overweight rating on the shares. The firm updated the company’s model t...

Simply Wall St 3d

BioMarin Is Down 6.5% After PALYNZIQ Pediatric Label Expansion Approval - Has The Bull Case Changed?

In late February 2026, BioMarin Pharmaceutical received U.S. FDA approval for a supplemental Biologics License Application expanding PALYNZIQ’s use to pediatric...

TipRanks 3d

Amicus Stockholders Approve BioMarin Acquisition at Special Meeting

Amicus ( (FOLD) ) just unveiled an announcement. On March 3, 2026, stockholders of Amicus Therapeutics approved the company’s acquisition by BioMarin Pharmaceu...

Analyst ratings

81%

of 26 ratings

Buy

80.8%

Hold

19.2%

Sell

More BMRN News

TipRanks 5d

BioMarin announces U.S FDA approved sBLA for Palynziq

BioMarin (BMRN) Pharmaceutical announced that the U.S. Food and Drug Administration, FDA, has approved the company’s supplemental Biologics License Application,...

Simply Wall St 6d

A Look At BioMarin Valuation After Recent Share Price Rebound And Undervaluation Debate

Advertisement Event driven snapshot of BioMarin Pharmaceutical BioMarin Pharmaceutical (BMRN) is back on investor radars after recent share price moves, with...

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.